Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Inclusion Criteria: * Male or female (inclusive) aged ≥ 18 and ≤ 70 years old at the time of signing informed consent. * Diagnosed with AATD and genetically confirmed as homozygous PiZZ mutation. * Blood total AAT level \< 11 μM or equivalent protein in mg/dL. * Patients receiving augmentation therapy must be willing to discontinue it at least 6 weeks prior to signing the informed consent form (ICF) and throughout the study period, unless clinically indicated. Exclusion criteria * Body mass index (BMI) \> 35 kg/m2. * Patients who have undergone lung or liver transplantation, are on the waiting list for lung or liver transplantation, or have had lung volume reduction surgery (LVRS). * Clinical evidence of severe bronchiectasis, as judged by the investigator (e.g., excessive sputum production or recurrent infections requiring antibiotics \[\> 4 times per year\]). * FEV1 ≤ 30% of predicted value after bronchodilator use at screening * Liver disease with any of the following: * Measured liver stiffness (FibroScan) ≥ 10 kilopascals (kPa). * Known history of hepatic cirrhosis or associated complications (e.g., varices, ascites, hepatic encephalopathy). * ≥ F2 hepatic fibrosis in patients with prior liver biopsy. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 1.5 times the upper limit of normal (ULN). * Total bilirubin \> ULN; or \> 2 times the ULN if Gilbert's syndrome is documented. * International normalized ratio (INR) ≥ 1.2 at screening.…